Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025;22(3):288-309.
doi: 10.2174/0115701794332632240918043021.

Advances in the Total Synthesis of Pharmacologically Important Fused Indolizidine Alkaloids: Securinine, Gephyrotoxin and Lepadiformine

Affiliations
Review

Advances in the Total Synthesis of Pharmacologically Important Fused Indolizidine Alkaloids: Securinine, Gephyrotoxin and Lepadiformine

Afiqah A A Ali et al. Curr Org Synth. 2025.

Abstract

Indolizidine alkaloids represent a diverse group of naturally occurring compounds which are derived from various sources and possess a wide range of pharmacological activities. Fused indolizidine alkaloids represent a distinct subset of these compounds, where additional rings are fused with the indolizidine core. When combined with the specific stereochemistry typically required for their biological activity, the fused ring structure complicates the synthesis of this important class of compounds. Among the well-studied fused indolizidine alkaloids are securinine, gephyrotoxin, and lepadiformine, which have all exhibited potential in important therapeutic areas. Due to their complex structures, over the years numerous approaches have been proposed to synthesize these compounds. In this article, we review the progress made in synthetic routes for these key fused indolizidine alkaloids throughout history, providing a broad overview and the distinct advantages of the various strategies that could be employed in their synthesis.

Keywords: Synthesis; gephyrotoxin; indolizidine alkaloids; lepadiformine; securinine; stereochemistry..

PubMed Disclaimer

References

    1. Zhang J.; Morris-Natschke S.L.; Ma D.; Shang X.F.; Yang C.J.; Liu Y.Q.; Lee K.H.; Biologically active indolizidine alkaloids. Med Res Rev 2021,41(2),928-960 - DOI - PubMed
    1. Takahata H.; Takefumi Momose A.N.D.; Simple indolizidine alkaloids. The alkaloids 1997,44,189-256
    1. Michael J.P.; Indolizidine and quinolizidine alkaloids. Nat Prod Rep 2005,22(5),603-626 - DOI - PubMed
    1. Ratmanova N.K.; Andreev I.A.; Leontiev A.V.; Momotova D.; Novoselov A.M.; Ivanova O.A.; Trushkov I.V.; Strategic approaches to the synthesis of pyrrolizidine and indolizidine alkaloids. Tetrahedron 2020,76(14),131031 - DOI
    1. Xie L.; Liang S.; Jiwa H.; Zhang L.; Lu Q.; Wang X.; Luo L.; Xia H.; Li Z.; Wang J.; Luo X.; Luo J.; Securinine inhibits the tumor growth of human bladder cancer cells by suppressing Wnt/β-catenin signaling pathway and activating p38 and JNK signaling pathways. Biochem Pharmacol 2024,223,116125 - DOI - PubMed

Publication types

MeSH terms